1
|
Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays. Curr Res Toxicol 2022; 3:100092. [PMID: 36353521 PMCID: PMC9637864 DOI: 10.1016/j.crtox.2022.100092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 10/06/2022] [Accepted: 10/26/2022] [Indexed: 11/05/2022] Open
Abstract
Toxicology in the 21st Century (Tox21) is a federal collaboration employing a high-throughput robotic screening system to test 10,000 environmental chemicals. One of the primary goals of the program is prioritizing toxicity evaluations through in vitro high-throughput screening (HTS) assays for large numbers of chemicals already in commercial use for which little or no toxicity data is available. Within the Tox21 screening program, disruption in nuclear receptor (NR) signaling represents a particular area of interest. Given the role of NR's in modulating a wide range of biological processes, alterations of their activity can have profound biological impacts. Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily that has demonstrated importance in bile acid homeostasis, glucose metabolism, lipid homeostasis and hepatic regeneration. In this study, we re-evaluated 24 FXR agonists and antagonists identified through Tox21 using select orthogonal assays. In transient transactivation assays, 7/8 putative agonists and 4/4 putative inactive compounds were confirmed. Likewise, we confirmed 9/12 antagonists tested. Using a mammalian two hybrid approach we demonstrate that both FXR agonists and antagonists facilitate FXRα-coregulator interactions suggesting that differential coregulator recruitment may mediate activation/repression of FXRα mediated transcription. Additionally, we tested the ability of select FXR agonists and antagonists to facilitate hepatic transcription of FXR gene targets Shp and Bsep in a teleost (Medaka) model. Through application of in vitro cell-based assays, in silico modeling and in vivo gene expressions, we demonstrated the molecular complexity of FXR:ligand interactions and confirmed the ability of diverse ligands to modulate FXRα, facilitate differential coregulator recruitment and activate/repress receptor-mediated transcription. Overall, we suggest a multiplicative approach to assessment of nuclear receptor function may facilitate a greater understanding of the biological and mechanistic complexities of nuclear receptor activities and further our ability to interpret broad HTS outcomes.
Collapse
Key Words
- Bsep, bile salt export pump
- CDCA, chenodeoxycholic acid
- DMSO, dimethyl sulfoxide
- EPA, U.S. Environmental Protection Agency
- FXR, Farnesoid X receptor
- Farnesoid X receptor
- High-throughput screening
- M2H, mammalian two-hybrid
- Medaka
- RXR, retinoid X receptor
- Shp, small heterodimer partner
- Teleost models
- Tox21, Toxicology in the 21st Century
- ToxCast
- qHTS, quantitative high-throughput screening
Collapse
|
2
|
Norona LM, Fullerton A, Lawson C, Leung L, Brumm J, Kiyota T, Maher J, Khojasteh C, Proctor WR. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk. Arch Toxicol 2020; 94:3185-3200. [PMID: 32583097 DOI: 10.1007/s00204-020-02804-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 06/15/2020] [Indexed: 11/29/2022]
Abstract
Drug-induced liver injury (DILI) continues to be a major cause of drug attrition and restrictive labeling. Given the importance of farnesoid X receptor (FXR) in bile acid homeostasis, drug-related FXR antagonism may be an important mechanism of DILI. However, a comprehensive assessment of this phenomenon broadly in the context of DILI is lacking. As such, we used an orthogonal approach comprising a FXR target gene assay in primary human hepatocytes and a commercially available FXR reporter assay to investigate the potential FXR antagonistic effects of an extensive test set of 159 compounds with and without association with clinical DILI. Data were omitted from analysis based on the presence of cytotoxicity to minimize false positive assay signals and other complications in data interpretation. Based on the experimental approaches employed and corresponding data, the prevalence of FXR antagonism was relatively low across this broad DILI test set, with 16-24% prevalence based on individual assay results or combined signals in both assays. Moreover, FXR antagonism was not highly predictive for identifying clinically relevant hepatotoxicants retrospectively, where FXR antagonist classification alone had minimal to moderate predictive value as represented by positive and negative likelihood ratios of 2.24-3.84 and 0.72-0.85, respectively. The predictivity did not increase significantly when considering only compounds with high clinical exposure (maximal or efficacious plasma exposures > 1.0 μM). In contrast, modest gains in predictive value of FXR antagonism were observed considering compounds that also inhibit bile salt export pump. In addition, we have identified novel FXR antagonistic effects of well-studied hepatotoxic drugs, including bosentan, tolcapone and ritonavir. In conclusion, this work represents a comprehensive evaluation of FXR antagonism in the context of DILI, including its overall predictivity and challenges associated with detecting this phenomenon in vitro.
Collapse
Affiliation(s)
- Leah M Norona
- Predictive Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, 94080, USA
| | - Aaron Fullerton
- Predictive Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, 94080, USA
| | - Chris Lawson
- Predictive Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, 94080, USA
| | - Leslie Leung
- Predictive Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, 94080, USA
| | - Jochen Brumm
- Non-Clinical Biostatistics, Product Development, Genentech, Inc., South San Francisco, CA, 94080, USA
| | - Tomomi Kiyota
- Predictive Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, 94080, USA
| | - Jonathan Maher
- Predictive Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, 94080, USA
| | - Cyrus Khojasteh
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, 94080, USA
| | - William R Proctor
- Predictive Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, 94080, USA.
| |
Collapse
|